Search

Your search keyword '"Borsotti, Chiara"' showing total 5 results
Start Over Author "Borsotti, Chiara" Publisher ferrata storti foundation
5 results on '"Borsotti, Chiara"'

1. Therapeutic potential of fetal liver cell transplantation in hemophilia A mice

Author

European Commission, Università degli Studi del Piemonte Orientale “A. Avogadro”, Roche, Junta de Andalucía, Agencia Estatal de Investigación (España), Merlin, Simone, Akula, S., Cottonaro, Alessia, García Leal, Tamara, Serrano, L. J., Borroni, Ester, Kalandadze, Vakhtang, Galiano, Rocío, Borsotti, Chiara, Liras, A., Sánchez, María José, Follenzi, Antonia, European Commission, Università degli Studi del Piemonte Orientale “A. Avogadro”, Roche, Junta de Andalucía, Agencia Estatal de Investigación (España), Merlin, Simone, Akula, S., Cottonaro, Alessia, García Leal, Tamara, Serrano, L. J., Borroni, Ester, Kalandadze, Vakhtang, Galiano, Rocío, Borsotti, Chiara, Liras, A., Sánchez, María José, and Follenzi, Antonia

Abstract

Hemophilia A (HA) cell therapy approaches in pediatric individuals require suitable factor (F)VIII-producing cells for stable engraftment. Liver sinusoidal endothelial cells (LSEC) and hematopoietic stem cells (HSC) have been demonstrated to be suitable for the treatment of adult HA mice. However, after transplantation in busulfan (BU)-conditioned newborn mice, adult LSEC/HSC cannot efficiently engraft, while murine fetal liver (FL) hemato/vascular cells from embryonic day 11-13 of gestation (E11-E13), strongly engraft the hematopoietic and endothelial compartments while also secreting FVIII. Our aim was to investigate the engraftment of FL cells in newborn HA mice to obtain a suitable “proof of concept” for the development of a new HA treatment in neonates. Hence, we transplanted FL E11 or E13 cells and adult bone marrow (BM) cells into newborn HA mice with or without BU preconditioning. Engraftment levels and FVIII activity were assessed starting from 6 weeks after transplantation. FL E11-E13+ BU transplanted newborns reached up to 95% engraftment with stable FVIII activity levels observed for 16 months. FL E13 cells showed engraftment ability even in the absence of BU preconditioning, while FL E11 cells did not. BM BU transplanted newborn HA mice showed high levels of engraftment; nevertheless, in contrast to FL cells, BM cells cannot engraft HA newborns in BU non-conditioning regimen. Finally, none of the transplanted mice developed anti-FVIII antibodies. Overall, this study sheds some light on the therapeutic potential of healthy FL cells in the cure of HA neonatal/pediatric patients.

Published
2023

2. Supplementary material of the article, Therapeutic potential of fetal liver cell transplantation in hemophilia A mice [Dataset]

Author

Merlin, Simone, Akula, S., Cottonaro, Alessia, García Leal, Tamara, Serrano, L. J., Borroni, Ester, Kalandadze, Vakhtang, Galiano, Rocío, Borsotti, Chiara, Liras, A., Fernández Sánchez, José María, Follenzi, Antonia, Merlin, Simone, Akula, S., Cottonaro, Alessia, García Leal, Tamara, Serrano, L. J., Borroni, Ester, Kalandadze, Vakhtang, Galiano, Rocío, Borsotti, Chiara, Liras, A., Fernández Sánchez, José María, and Follenzi, Antonia

Published
2023

3. Factor VIII promotes angiogenesis and vessel stability regulating extracellular matrix proteins.

Author

Olgasi C, Cucci A, Molineris I, Assanelli S, Anselmi F, Borsotti C, Sgromo C, Lauria A, Merlin S, Walker GE, Oliviero S, and Follenzi A

Subjects
Humans, Animals, Neovascularization, Physiologic, Mice, Neovascularization, Pathologic metabolism, Neovascularization, Pathologic pathology, Angiogenesis, Extracellular Matrix Proteins metabolism, Factor VIII metabolism
Published
2024
Full Text
View/download PDF

4. Therapeutic potential of fetal liver cell transplantation in hemophilia A mice.

Author

Merlin S, Akula S, Cottonaro A, Garcia-Leal T, Serrano LJ, Borroni E, Kalandadze V, Galiano R, Borsotti C, Liras A, Sanchez MJ, and Follenzi A

Subjects
Mice, Animals, Endothelial Cells, Liver, Hematopoietic Stem Cells, Stem Cell Transplantation, Busulfan, Mice, Inbred C57BL, Hemophilia A therapy, Hematopoietic Stem Cell Transplantation
Abstract

Hemophilia A (HA) cell therapy approaches in pediatric individuals require suitable factor (F)VIII-producing cells for stable engraftment. Liver sinusoidal endothelial cells (LSEC) and hematopoietic stem cells (HSC) have been demonstrated to be suitable for the treatment of adult HA mice. However, after transplantation in busulfan (BU)-conditioned newborn mice, adult LSEC/HSC cannot efficiently engraft, while murine fetal liver (FL) hemato/vascular cells from embryonic day 11-13 of gestation (E11-E13), strongly engraft the hematopoietic and endothelial compartments while also secreting FVIII. Our aim was to investigate the engraftment of FL cells in newborn HA mice to obtain a suitable "proof of concept" for the development of a new HA treatment in neonates. Hence, we transplanted FL E11 or E13 cells and adult bone marrow (BM) cells into newborn HA mice with or without BU preconditioning. Engraftment levels and FVIII activity were assessed starting from 6 weeks after transplantation. FL E11-E13+ BU transplanted newborns reached up to 95% engraftment with stable FVIII activity levels observed for 16 months. FL E13 cells showed engraftment ability even in the absence of BU preconditioning, while FL E11 cells did not. BM BU transplanted newborn HA mice showed high levels of engraftment; nevertheless, in contrast to FL cells, BM cells cannot engraft HA newborns in BU non-conditioning regimen. Finally, none of the transplanted mice developed anti-FVIII antibodies. Overall, this study sheds some light on the therapeutic potential of healthy FL cells in the cure of HA neonatal/pediatric patients.

Published
2023
Full Text
View/download PDF

5. Reduced intensity conditioning allogeneic transplant for advanced chronic lymphocytic leukemia.

Author

Soligo D, Motta M, Borsotti C, Ibatici A, Cortelezzi A, and Lambertenghi Deliliers G

Subjects
Humans, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Neoplasm Staging, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Transplantation Conditioning
Abstract

We report the preliminary results of 12 patients with advanced stage chronic lymphocytic leukemia (CLL) transplanted following reduced intensity conditioning (RIC. With a median of 22 months of follow-up, 9 patients are alive and 3 have died of progressive disease, graft-versus-host disease (GVHD) or toxic hepatitis. Acute grade I-III GVHD occurred in 33% of patients and chronic GVHD in 50%. Eight of the 12 patients achieved a complete remission (CR) and 2 patients a partial remission (PR). Donor lymphocyte infusion was effective in 6 patients. Event-free survival, progression-free survival and non-relapse mortality at 3 years were 68%, 42% and 16%, respectively. Our results show successful immunomodulation and reduction in tumor burden in high risk CLL.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results